Skip to Content

Notice

Advisory Committee Renewals

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is announcing the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the charters of the committees listed in the following table for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed in the following table. This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app.).

DATES:

Authority for these committees will expire on the dates indicated in the following table unless the Commissioner formally determines that renewal is in the public interest.

Name of committeeDate of expiration
Cardio and Renal Drugs Advisory CommitteeAugust 27, 2016.
Endocrinologic and Metabolic Drugs Advisory CommitteeAugust 27, 2016.
Oncologic Drugs Advisory CommitteeSeptember 1, 2016.
Anti-Infective Drugs Advisory CommitteeOctober 7, 2016.
Dermatologic and Ophthalmic Drugs Advisory CommitteeOctober 7, 2016.
Cellular, Tissue, and Gene Therapies Advisory CommitteeOctober 28, 2016.
Technical Electronic Product Radiation Safety Standards CommitteeDecember 24, 2016.
Start Further Info

FOR FURTHER INFORMATION CONTACT:

Michael Ortwerth, Director, Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-443-0572 or 1-800-741-8138. For further information related to FDA advisory committees, please visit us at http://www.fda.gov/​AdvisoryCommittees/​default.htm.

Start Signature

Dated: February 6, 2015.

Leslie Kux,

Associate Commissioner for Policy.

End Signature End Further Info End Preamble

[FR Doc. 2015-02909 Filed 2-11-15; 8:45 am]

BILLING CODE 4164-01-P